GlobeNewswire Inc | Sep 8, 2021 08:30AM EDT

September 08, 2021

JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September.

Presentation details can be found below:

-- H.C. Wainwright 23rd Annual Global Investment ConferenceFormat: On demand presentation and 1-on-1 meetingsDate and Time: Presentation available Monday, September 13 at 7 am ET, 1-on-1 meetings September 13-15Registration Link

-- Cantor Fitzgerald Virtual Global Healthcare ConferenceFormat: Live presentation and 1-on-1 meetingsDate and Time: Thursday, September 30 from 2:40-3:10 pm ET (Track 2)

The presentations and archived webcasts can be found on the SCYNEXIS website at: https://www.scynexis.com/news-media/events for 30 days following the event.

AboutSCYNEXISSCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the companys lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME(ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visitwww.scynexis.com.

CONTACTInvestor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com